{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:40:52Z","timestamp":1781124052615,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many studies have found that systemic inflammation plays an important role in the pathogenesis of atrial fibrillation (AF). Gout is a chronic systemic inflammatory disorder, but little evidence exists regarding whether the risk of AF is increased in patients with gout. The National Health Insurance Research Database in Taiwan was used in this study and gout was defined as the occurrence of at least one episode of an acute gout attack requiring medical treatment. A total of 63264 gout and 63264 age- and gender-matched patients were included as the study population. The Cox model was used to evaluate the risk of AF in patients with gout. Patients with gout experienced a greater frequency of co-morbidities compared to patients without gout. The cumulative incidences of AF were 4.61% and 3.04% in patients with and without gout, respectively (log-rank test, P\u2009&lt;\u20090.001). After adjusting for co-morbidities and prescription medication use, gout was found to be associated with AF [hazard ratio (HR), 1.38]. Moreover, the HR for AF decreased with increasing age in our study. Gout was found to be associated with an increased risk of developing AF after adjusting for potential confounders.<\/jats:p>","DOI":"10.1038\/srep32220","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T09:51:01Z","timestamp":1473241861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The risk of atrial fibrillation in patients with gout: a nationwide population-based study"],"prefix":"10.1038","volume":"6","author":[{"given":"Yu-Jui","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ping","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Ying","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Jen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ling","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"BFsrep32220_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/CIRCRESAHA.114.303215","volume":"114","author":"PM Ridker","year":"2014","unstructured":"Ridker, P. M. Inflammation, C-reactive protein and cardiovascular disease: moving past the marker versus mediator debate. Circulation research 114, 594\u2013595 (2014).","journal-title":"Circulation research"},{"key":"BFsrep32220_CR2","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/eurheartj\/ehp477","volume":"30","author":"R Klingenberg","year":"2009","unstructured":"Klingenberg, R. & Hansson, G. K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European heart journal 30, 2838\u20132844 (2009).","journal-title":"European heart journal"},{"key":"BFsrep32220_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/15257771003738709","volume":"29","author":"JM Fraile","year":"2010","unstructured":"Fraile, J. M. et al. Metabolic syndrome characteristics in gout patients. Nucleosides, nucleotides & nucleic acids 29, 325\u2013329 (2010).","journal-title":"Nucleosides, nucleotides & nucleic acids"},{"key":"BFsrep32220_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi, H. K., Ford, E. S., Li, C. & Curhan, G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis and rheumatism 57, 109\u2013115 (2007).","journal-title":"Arthritis and rheumatism"},{"key":"BFsrep32220_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1136\/heartjnl-2013-305099","volume":"100","author":"NH Kim","year":"2014","unstructured":"Kim, N. H. et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100, 938\u2013943 (2014).","journal-title":"Heart"},{"key":"BFsrep32220_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2005.11.074","volume":"47","author":"Y He","year":"2006","unstructured":"He, Y. et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. Journal of the American College of Cardiology 47, 1588\u20131594 (2006).","journal-title":"Journal of the American College of Cardiology"},{"key":"BFsrep32220_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/eurheartj\/ehi717","volume":"27","author":"J Dallongeville","year":"2006","unstructured":"Dallongeville, J. et al. Association between the metabolic syndrome and parental history of premature cardiovascular disease. European heart journal 27, 722\u2013728 (2006).","journal-title":"European heart journal"},{"key":"BFsrep32220_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","volume":"110","author":"S Malik","year":"2004","unstructured":"Malik, S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Circulation 110, 1245\u20131250 (2004).","journal-title":"Circulation"},{"key":"BFsrep32220_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2009.122770","volume":"69","author":"MA De Vera","year":"2010","unstructured":"De Vera, M. A., Rahman, M. M., Bhole, V., Kopec, J. A. & Choi, H. K. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Annals of the rheumatic diseases 69, 1162\u20131164 (2010).","journal-title":"Annals of the rheumatic diseases"},{"key":"BFsrep32220_CR10","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan, E., Baker, J. F., Furst, D. E. & Schumacher, H. R. Gout and the risk of acute myocardial infarction. Arthritis and rheumatism 54, 2688\u20132696 (2006).","journal-title":"Arthritis and rheumatism"},{"key":"BFsrep32220_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11926-008-0039-0","volume":"10","author":"E Krishnan","year":"2008","unstructured":"Krishnan, E. Gout and coronary artery disease: epidemiologic clues. Current rheumatology reports 10, 249\u2013255 (2008).","journal-title":"Current rheumatology reports"},{"key":"BFsrep32220_CR12","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/rheumatology\/ket293","volume":"52","author":"OO Seminog","year":"2013","unstructured":"Seminog, O. O. & Goldacre, M. J. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford) 52, 2251\u20132259 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32220_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/rheumatology\/kes169","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo, C. F. et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52, 111\u2013117 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32220_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke; a journal of cerebral circulation 22, 983\u2013988 (1991).","journal-title":"Stroke; a journal of cerebral circulation"},{"key":"BFsrep32220_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.cir.0000442015.53336.12","volume":"129","author":"AS Go","year":"2014","unstructured":"Go, A. S. et al. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 129, 399\u2013410 (2014).","journal-title":"Circulation"},{"key":"BFsrep32220_CR16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/HJH.0000000000000112","volume":"32","author":"F Angeli","year":"2014","unstructured":"Angeli, F., Reboldi, G. & Verdecchia, P. Hypertension, inflammation and atrial fibrillation. Journal of hypertension 32, 480\u2013483 (2014).","journal-title":"Journal of hypertension"},{"key":"BFsrep32220_CR17","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2012.04.063","volume":"60","author":"Y Guo","year":"2012","unstructured":"Guo, Y., Lip, G. Y. & Apostolakis, S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology 60, 2263\u20132270 (2012).","journal-title":"Journal of the American College of Cardiology"},{"key":"BFsrep32220_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.hrthm.2009.12.009","volume":"7","author":"J Li","year":"2010","unstructured":"Li, J. et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart rhythm: the official journal of the Heart Rhythm Society 7, 438\u2013444 (2010).","journal-title":"Heart rhythm: the official journal of the Heart Rhythm Society"},{"key":"BFsrep32220_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1161\/CIRCULATIONAHA.107.744466","volume":"117","author":"H Watanabe","year":"2008","unstructured":"Watanabe, H. et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 117, 1255\u20131260 (2008).","journal-title":"Circulation"},{"key":"BFsrep32220_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.amjcard.2011.03.026","volume":"108","author":"RM Tanner","year":"2011","unstructured":"Tanner, R. M. et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). The American journal of cardiology 108, 227\u2013232 (2011).","journal-title":"The American journal of cardiology"},{"key":"BFsrep32220_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ahj.2010.02.005","volume":"159","author":"AM Chamberlain","year":"2010","unstructured":"Chamberlain, A. M. et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. American heart journal 159, 850\u2013856 (2010).","journal-title":"American heart journal"},{"key":"BFsrep32220_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.hrthm.2009.10.027","volume":"7","author":"S Dixit","year":"2010","unstructured":"Dixit, S. Atrial fibrillation and inflammation: quest for the missing link in the etiopathogenesis of AF. Heart rhythm: the official journal of the Heart Rhythm Society 7, 155\u2013156 (2010).","journal-title":"Heart rhythm: the official journal of the Heart Rhythm Society"},{"key":"BFsrep32220_CR23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.107.760777","volume":"117","author":"JT Nguyen","year":"2008","unstructured":"Nguyen, J. T. & Benditt, D. G. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 117, 1249\u20131251 (2008).","journal-title":"Circulation"},{"key":"BFsrep32220_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.numecd.2014.03.012","volume":"24","author":"SY Chuang","year":"2014","unstructured":"Chuang, S. Y. et al. Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan. Nutrition, metabolism and cardiovascular diseases: NMCD 24, 1020\u20131026 (2014).","journal-title":"Nutrition, metabolism and cardiovascular diseases: NMCD"},{"key":"BFsrep32220_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijcard.2013.11.011","volume":"170","author":"TF Chao","year":"2014","unstructured":"Chao, T. F. et al. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation\u2013could it refine clinical risk stratification in AF? International journal of cardiology 170, 344\u2013349 (2014).","journal-title":"International journal of cardiology"},{"key":"BFsrep32220_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijcard.2009.01.018","volume":"144","author":"LF Drager","year":"2010","unstructured":"Drager, L. F., Bortolotto, L. A., Pedrosa, R. P., Krieger, E. M. & Lorenzi-Filho, G. Left atrial diameter is independently associated with arterial stiffness in patients with obstructive sleep apnea: potential implications for atrial fibrillation. International journal of cardiology 144, 257\u2013259 (2010).","journal-title":"International journal of cardiology"},{"key":"BFsrep32220_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/rheumatology\/ket444","volume":"53","author":"KL Pan","year":"2014","unstructured":"Pan, K. L. et al. The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. Rheumatology (Oxford) 53, 867\u2013874 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32220_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/10641963.2012.746351","volume":"35","author":"S Yilmaz","year":"2013","unstructured":"Yilmaz, S., Celik, G. & Gundogdu, A. Assessment of arterial stiffness in female and male gout patients. Clinical and experimental hypertension 35, 430\u2013436 (2013).","journal-title":"Clinical and experimental hypertension"},{"key":"BFsrep32220_CR29","doi-asserted-by":"crossref","unstructured":"Schmidt, M., Christiansen, C. F., Mehnert, F., Rothman, K. J. & Sorensen, H. T. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 343, doi: 10.1136\/bmj.d3450 (2011).","DOI":"10.1136\/bmj.d3450"},{"key":"BFsrep32220_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrcardio.2010.173","volume":"7","author":"H Myrvang","year":"2010","unstructured":"Myrvang, H. Pharmacotherapy: Association between NSAIDs and risk of atrial fibrillation. Nature reviews. Cardiology 7, 668 (2010).","journal-title":"Nature reviews. Cardiology"},{"key":"BFsrep32220_CR31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/ard.2011.200523","volume":"71","author":"GG Teng","year":"2012","unstructured":"Teng, G. G. et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Annals of the rheumatic diseases 71, 924\u2013928 (2012).","journal-title":"Annals of the rheumatic diseases"},{"key":"BFsrep32220_CR32","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","volume":"74","author":"LE Clarson","year":"2014","unstructured":"Clarson, L. E. et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK Clinical Practice Research Datalink. Annals of the rheumatic diseases 74, 642\u2013647(2014).","journal-title":"Annals of the rheumatic diseases"},{"key":"BFsrep32220_CR33","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1016\/j.ijcard.2013.06.067","volume":"168","author":"TF Chao","year":"2013","unstructured":"Chao, T. F. et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. International journal of cardiology 168, 4027\u20134032 (2013).","journal-title":"International journal of cardiology"},{"key":"BFsrep32220_CR34","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1136\/bmj.e1257","volume":"344","author":"J Lindhardsen","year":"2012","unstructured":"Lindhardsen, J. et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 344, e1257, doi: 10.1136\/bmj.e1257 (2012).","journal-title":"BMJ"},{"key":"BFsrep32220_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/annrheumdis-2014-206432","volume":"74","author":"JA Singh","year":"2015","unstructured":"Singh, J. A. When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Annals of the rheumatic diseases 74, 631\u2013634 (2015).","journal-title":"Annals of the rheumatic diseases"},{"key":"BFsrep32220_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1161\/STROKEAHA.113.000883","volume":"44","author":"IE Albertsen","year":"2013","unstructured":"Albertsen, I. E. et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke; a journal of cerebral circulation 44, 1329\u20131336 (2013).","journal-title":"Stroke; a journal of cerebral circulation"},{"key":"BFsrep32220_CR37","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan, K. M. et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372\u20131374 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32220_CR38","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research 64, 1431\u20131446 (2012).","journal-title":"Arthritis care & research"},{"key":"BFsrep32220_CR39","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh, S. S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129, 837\u2013847 (2014).","journal-title":"Circulation"},{"key":"BFsrep32220_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","volume":"11","author":"F Rahman","year":"2014","unstructured":"Rahman, F., Kwan, G. F. & Benjamin, E. J. Global epidemiology of atrial fibrillation. Nature reviews. Cardiology 11, 639\u2013654 (2014).","journal-title":"Nature reviews. Cardiology"},{"key":"BFsrep32220_CR41","first-page":"e941","volume":"125","author":"M Rienstra","year":"2012","unstructured":"Rienstra, M., McManus, D. D. & Benjamin, E. J. Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation 125, e941\u2013946 (2012).","journal-title":"Circulation"},{"key":"BFsrep32220_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/annrheumdis-2012-202023","volume":"72","author":"O Slot","year":"2013","unstructured":"Slot, O. Homocysteine, a marker of cardiovascular disease risk, is markedly elevated in patients with gout. Annals of the rheumatic diseases 72, 457 (2013).","journal-title":"Annals of the rheumatic diseases"},{"key":"BFsrep32220_CR43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jacc.2011.05.028","volume":"58","author":"V Veeranna","year":"2011","unstructured":"Veeranna, V. et al. Homocysteine and reclassification of cardiovascular disease risk. Journal of the American College of Cardiology 58, 1025\u20131033 (2011).","journal-title":"Journal of the American College of Cardiology"},{"key":"BFsrep32220_CR44","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","volume":"33","author":"C Borghi","year":"2015","unstructured":"Borghi, C. et al. Serum uric acid and the risk of cardiovascular and renal disease. Journal of hypertension 33, 1729\u20131741 (2015).","journal-title":"Journal of hypertension"},{"key":"BFsrep32220_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/art.24164","volume":"61","author":"JH Chen","year":"2009","unstructured":"Chen, J. H., Chuang, S. Y., Chen, H. J., Yeh, W. T. & Pan, W. H. Serum uric acid level as an independent risk factor for all-cause, cardiovascular and ischemic stroke mortality: a Chinese cohort study. Arthritis and rheumatism 61, 225\u2013232 (2009).","journal-title":"Arthritis and rheumatism"},{"key":"BFsrep32220_CR46","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jama.300.7.795","volume":"300","author":"M Ebbing","year":"2008","unstructured":"Ebbing, M. et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA: the journal of the American Medical Association 300, 795\u2013804 (2008).","journal-title":"JAMA: the journal of the American Medical Association"},{"key":"BFsrep32220_CR47","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1001\/archinternmed.2010.348","volume":"170","author":"R Clarke","year":"2010","unstructured":"Clarke, R. et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Archives of internal medicine 170, 1622\u20131631 (2010).","journal-title":"Archives of internal medicine"},{"key":"BFsrep32220_CR48","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"JM Hare","year":"2008","unstructured":"Hare, J. M. et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. Journal of the American College of Cardiology 51, 2301\u20132309 (2008).","journal-title":"Journal of the American College of Cardiology"},{"key":"BFsrep32220_CR49","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz, M. M. et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 131, 1763\u20131771 (2015).","journal-title":"Circulation"},{"key":"BFsrep32220_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","volume":"22","author":"TM Cheng","year":"2003","unstructured":"Cheng, T. M. Taiwan\u2019s new national health insurance program: genesis and experience so far. Health affairs 22, 61\u201376 (2003).","journal-title":"Health affairs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32220","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T20:50:10Z","timestamp":1672865410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,17]]}},"alternative-id":["BFsrep32220"],"URL":"https:\/\/doi.org\/10.1038\/srep32220","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"assertion":[{"value":"7 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32220"}}